Source: Bar and Bench

Ahmedabad-based drug maker Zydus Cadila has acquired six brands from the Indian unit of US pharmaceutical giant Merck for an undisclosed amount.

Deal Zydus Cadila acquires six brands from Merck
Value  NA
Deal Type M&A
Sector Healthcare
Law Firms Cyril Amarchand Mangaldas – Zydus Cadila; Nisith Desai Associates – Merck
Partners/Heads Cyril Amarchand Mangaldas – Smruti Shah and Anshuman Sakle; Nishith Desai Associates – Gowree Gokhale

Law Firms Cyril Amarchand Mangaldas – Zydus Cadila; Nisith Desai Associates – Merck

Partners/Heads Cyril Amarchand Mangaldas – Smruti Shah and Anshuman Sakle; Nishith Desai Associates – Gowree Gokhale

Cyril Amarchand Mangaldas advised Zydus Cadila with a team led by Mumbai based corporate partner Smruti Shah along with competition law partner Anshuman Sakle.

Nishith Desai Associates advised Merck and the team included Partner Gowree Gokhale, Senior Associate Aarushi Jain and Associate Pooja Kapadia.

Zydus has acquired Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten from Merck Sharp and Dohme (MSD). These brands fall in the men’s and women’s health, wound management and cardiovascular therapy segments.